Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$1.08 USD
+0.02 (1.89%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.09 +0.01 (0.93%) 7:52 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Oncolytics Biotech Inc. (ONCY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.73 | $6.63 | $2.22 | 346.23% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Oncolytics Biotech Inc. comes to $4.73. The forecasts range from a low of $2.22 to a high of $6.63. The average price target represents an increase of 346.23% from the last closing price of $1.06.
Analyst Price Targets (6 )
Broker Rating
Oncolytics Biotech Inc. currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 57.14% and 42.86% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 3 | 3 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.43 | 1.43 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/4/2024 | Raymond James Ltd. | Rahul Sarugaser | Not Available | Moderate Buy |
3/8/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
2/8/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
2/2/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
1/12/2024 | Cantor Fitzgerald & Co | Louise Chen | Not Available | Strong Buy |
10/17/2023 | Leede Jones Gable | Douglas W Loe | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 7 |
Average Target Price | $4.73 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -0.09 |